Rights Issue Offer Document

1
RIGHTS ISSUE OFFER DOCUMENT
1 for 3 renounceable rights offer of ordinary shares
Dated 21 February 2024
TruScreen Group Limited
This Offer Document is an important document. You should read the
whole document before deciding what action to take with your Rights.
If you have any doubts as to what you should do, please consult your
broker, financial, investment or other professional advisor. This Offer
Document may not be distributed outside New Zealand or Australia.

2
Important Information3
Letter from the Chair5
Key Terms of the Offer 7
Important Dates 8
Actions to be taken by Eligible Shareholders9
Business Overview12
Terms of the Offer15
Glossary 20
Contents
2

3
Important Information
General Information
This Offer Document has been prepared by
TruScreen Group Limited (TruScreen) in connection
with a 1 for 3 renounceable rights offer of New
Shares.
The Offer is made to Eligible Shareholders in New
Zealand pursuant to the exclusion in clause 19 of
schedule 1 of the Financial Markets Conduct Act
2013 (FMCA).
This Offer Document is not a product disclosure
statement for the purposes of the FMCA, and does
not contain all of the information that an investor
would find in a product disclosure statement
or which may be required to make an informed
decision about the Offer or TruScreen.
The Offer is made to Eligible Shareholders
in Australia pursuant to the provisions of the
Corporations Act 2001 (Cth) (Corporations Act) (as
modified by Australian Securities and Investments
Commission (ASIC) Corporations (Non-Traditional
Rights Issues) Instrument 2016/84 (ASIC Instrument
2016/84) and ASIC Instrument 23-0122. The Rights
will not be quoted on the NZX Main Board or the
Australian Securities Exchange (ASX).
This Offer Document is not a prospectus, product
disclosure statement or any other formal disclosure
document for the purposes of Australian law
or the Corporations Act and is not required to,
and does not, contain all the information which
would be required in a disclosure document
under Australian law or the Corporations Act. It
may contain references to dollar amounts which
are not Australian dollars, may contain financial
information which is not prepared in accordance
with Australian law or practices, may not address
risks associated with investment in foreign currency
denominated investments and does not address
Australian tax issues. TruScreen is a company which
is incorporated in New Zealand and the relationship
between it and investors will be largely governed
by New Zealand law.
This Offer Document has not been, and will not be,
lodged or registered with ASIC and TruScreen is not
subject to the continuous disclosure requirements
under the Corporations Act or the ASX Listing
Rules. TruScreen is only required to comply with the
continuous disclosure rules of the NZX Listing Rules.
Prospective investors should not construe anything
in this Offer Document as legal, business or tax
advice nor as financial product advice for the
purposes of Chapter 7 of the Corporations Act.
Additional information available under TruScreen’s
disclosure obligations
TruScreen is subject to continuous disclosure
obligations under the NZX Listing Rules. Further
information relating to the Offer can also be found
in TruScreen’s recent market announcements and
its most recent unaudited financial statements for
the six-month period ended 30 September 2023,
which can be accessed online at www.nzx.com
under the ticker code “TRU”.
TruScreen may, during the Offer, make additional
releases to NZX. To the maximum extent permitted
by law, no release by TruScreen to NZX will permit
an Applicant to withdraw any previously submitted
Application without TruScreen’s prior consent.
We encourage you to read this document and to
seek investment advice from a suitably qualified
professional adviser before you consider investing.
Offering restrictions
This Offer Document is intended for use only in
connection with the Offer to Eligible Shareholders.
To be an Eligible Shareholder you must be:
• A Shareholder with a registered address in New
Zealand; or
• A Shareholder with a registered address in
Australia.
This Offer Document does not constitute an offer or
invitation in any country in which, or to any person
to whom, it would not be lawful to make such an
offer or invitation.
This Offer Document may not be sent or given to
any person outside New Zealand or Australia. The
distribution of this Offer Document (including an
electronic copy) outside New Zealand or Australia
may be restricted by law. In particular, this Offer
Document may not be distributed to any person,
and the New Shares may not be offered or sold,
in any country outside New Zealand or Australia
except as detailed in this Offer Document, or as
TruScreen may otherwise determine in compliance
with applicable laws.
Neither this Offer Document nor the Application
Form may be released or distributed in the United
States of America.

4
Important Information
No guarantee
No guarantee is provided by any person in relation
to the New Shares to be issued under the Offer.
Likewise, no warranty is provided about the
future performance of TruScreen or any return
on any investment made pursuant to this Offer
Document. Eligible Shareholders should be aware
that there are risks associated with investing in
the New Shares. The principal risk is that Eligible
Shareholders may not be able to recoup the
Issue Price and/or may not receive any dividends,
entitlements, or other distributions in respect of the
New Shares. In addition, the market for the New
Shares may not be liquid. If liquidity is low, Eligible
Shareholders may be unable to sell their New
Shares at an acceptable price or at all.
Privacy
Any personal information provided in your
Application will be held by TruScreen and the
Registrar at the addresses set out in the Directory.
This information will be used for the purposes of
administering your investment in TruScreen and will
be disclosed to third parties only with your consent
or if required by law. Under the Privacy Act 2020
(New Zealand) you have the right to access and
correct any personal information held about you.
Dividend policy
The payment of dividends is at the discretion of the
Board. The Board has no present intention to make
a distribution for the foreseeable future. This policy
may change from time to time at the discretion of
the Board in the future.
Decision to participate in the Offer
The information in this Offer Document does not
constitute a recommendation to acquire New
Shares nor does it amount to financial product
advice. This Offer Document has been prepared
without taking into account the particular needs
or circumstances of any Applicant or investor,
including their investment objectives, financial
or tax position. Before deciding whether to
invest in the New Shares, you must make your
own assessment of the risks associated with an
investment in TruScreen, and consider whether
such an investment in TruScreen is suitable for you
having regard to publicly available information
about TruScreen, your personal circumstances and
following consultation with a financial adviser or
other professional adviser.
Forward looking statements
This document contains certain statements that
relate to the future. Such forward looking statements
are not a guarantee of future performance and
involve known and unknown risks, uncertainties,
assumptions and other factors, many of which
are beyond the control of TruScreen and which
may cause the actual results, performance or
achievements of TruScreen to differ materially from
those expressed or implied by such statements.
Under no circumstances should you regard the
inclusion of forward looking statements in this
document as a guarantee of future performance.
The statements, although made in good faith,
involve known and unknown risks, uncertainties,
and assumptions, many of which are beyond the
control of TruScreen.
Withdrawal and date changes
Subject to compliance with all applicable laws,
TruScreen reserves the right at its absolute
discretion to:
• withdraw all or any part of the Offer and the
issue of New Shares; and/or
• alter any dates set out in this Offer Document.
Enquiries
Enquiries about the Offer can be directed to an
NZX Firm, an authorised financial advisor, or your
solicitor, accountant, or other professional adviser.
If you have any questions about the number of New
Shares shown on your Entitlement and Acceptance
Form, or how to complete the Entitlement and
Acceptance Form or online application, please
contact the Registrar, whose contact details are
set out in the Directory.
Times, currency, and laws
All references in this Offer Document to times and
dates are to times and dates in New Zealand.
All references in this Offer Document to currency
are to New Zealand dollars, and all references to
applicable statutes and regulations are references
to New Zealand statutes and regulations.
Defined terms
Capitalised terms used in this Offer Document
have the meaning given to them in the Glossary in
the relevant section of this Offer Document.

5
Letter from the Chair
With product sales growth of 40% for the first
9 months to 31 December 2023, TruScreen
requires growth capital to fund expanded
working capital requirements. The accelerating
sales growth came from China, our major
market. We are also expecting positive
revenue contributions from Zimbabwe, Middle
East, and Vietnam in the final 3 months of the
financial year.
In CY2023 we made significant growth in China
with the successful inclusion and recognition
of TruScreen in two major national cervical
cancer screening Guidelines, by the Chinese
Society of Colposcopy and Cervical Pathology
(CSCCP), published in the July 2023 edition of
CSCCP’s journal and in the prestigious China
Obsterics and Gynaecological Association
(COGA) Blue Book in China. A subsequent
roadshow in several economic regions by our
distributor, Beijing Siweixiangtai Tech Co. Ltd
(SWXT), has demonstrated a growing sales
pipeline.
Saudi Arabia has commenced commercial
operations in Q2 FY2024 with TruScreen
placed in the largest private hospital network
in the Middle East. Our distributor, BetterLife,
successfully listed the TruScreen cervical
cancer screening procedure for private health
insurance reimbursement. This will reduce the
cost of the TruScreen procedure for those
patients with private health insurance.
In Vietnam, TruScreen has been included
in the Ministry of Health National Technical
List, enabling speedier implementation of
our technology in public hospitals. Four more
major cervical cancer screening hospitals are
pending approval of TruScreen with strong
local authorities support.
In Poland, TruScreen was awarded the top
prize in an international challenge of medical
technology companies, for implementation
in the country’s largest woman health public
hospital network. TruScreen has recently
received approval from the national regulator
in Mexico, Cofepris, for use of TruScreen®
Ultra device for cervical cancer screening
in the public health sector and inclusion
in government cervical cancer screening
programs. This is a major achievement by our
distributor, Sunbird Medical, after many years
of commercialisation in Mexico.
In Zimbabwe, we collaborate with the National
Aids Council (NAC), and deal directly with
the Ministry of Health (MOH). NAC have now
screened a total of 14,000 women in Masvingo
province. TruScreen has recently sold 10,800
SUS to MOH, giving a strong start to Q4
FY2024 sales. We expect 2024 will see further
expansion of the point-of-care screening in
Zimbabwe.
The TruScreen
®
Ultra is an AI enabled, primary
cervical cancer screening device, at the
leading edge of cervical cancer screening,
with outstanding results from major clinical
trials. The Company has a low overhead
Australian base, supported by distributors
in 20 countries, a manufacturing facility in
Australia, and China for devices marketed and
sold in China.
Eligible Shareholders are entitled to take up
one New Share for every three Existing Shares
held. Any Shortfall will be offered to investors
through a Shortfall Bookbuild process. Eligible
Shareholders are also able to apply for any
Shortfall through the Shortfall Bookbuild.
Any Premium above the Issue Price that is
achieved in the Shortfall Bookbuild will be
shared between those Shareholders who did
not, or were unable to, take up their Rights, in
proportion to the number of Rights not taken up.
Dear fellow shareholder,
On behalf of the directors of TruScreen Group Limited we are pleased to offer Eligible Shareholders
the opportunity to participate in a 1 for 3 renounceable rights issue at an issue price of NZ$0.02 per
share (A$0.0187), to raise up to NZ$2,800,168 (or A$2,612,585). This represents a discount of 23% on
the market price on 5 February 2024.

6
Letter from the Chair
Eligible Shareholders have until 5:00pm (NZDT)
on 13 March 2024 to apply for New Shares
under the Offer.
Shareholders who choose not to take up their
Rights entitlements will have their percentage
shareholding diluted, but may receive some
value through the Shortfall Bookbuild if a
Premium is payable.
This document sets out important information
about TruScreen and the Offer. Before making
your investment decision, I encourage you
to read these documents in full and also
to consider the information disclosed by
TruScreen to NZX and other information
available at www.nzx.com under the ticker
code “TRU”.
If you are in doubt as to what you should do,
you should consult your financial or professional
adviser.
I advise that directors who hold shares in
TruScreen intend to take up their full entitlement
of Rights.
TruScreen is at an important point of our
commercialisation journey. Sales of our
Single Use Sensor (SUS) are accelerating
with the growing number of our TruScreen
®

Ultra devices installed in commercial use. I
commend this Offer to Eligible Shareholders
to enable TruScreen to achieve its growth
objectives.
Yours sincerely
Tony Ho
Chairman
TruScreen Group Limited

7
Key Terms of the Offer
Issuer TruScreen Group Limited.
The Offer
A renounceable rights offer of one New Share for every three Existing
Shares held on the Record Date (being 5.00pm (NZDT), 20 February
2024), with fractional entitlements being rounded down to the
nearest share, followed by a Shortfall Bookbuild.
Eligible Shareholders
Shareholders with registered addresses in New Zealand or Australia
on the Record Date.
Issue Price
NZ$0.02 or (A$0.0187, being the A$ price) per New Share.
Any New Shares issued under the Shortfall Bookbuild will be issued
at the Bookbuild Price.
Shortfall Bookbuild
Eligible Shareholders who take up their Rights in full have the
opportunity to apply for additional New Shares which are attributable
to any Rights not taken up. These applications for additional New
Shares will go into a Shortfall Bookbuild process which may also
involve other investors.
Offer Size
Up to NZ$2,800,168 (or A$2,612,585). In the event that TruScreen
receives subscriptions for more than NZ$2,800,168 under the Offer it
reserves the right to issue additional Shares under the 15% placement
Listing Rule or in any other manner it may lawfully do so.
Shares currently on issue420,025,339 Shares quoted on the NZX Main Board.
Maximum number of New
Shares being
offered
140,008,446 New Shares (subject to rounding, and to TruScreen’s
right to issue further shares under the Listing Rules).
Rights
Eligible Shareholders have an entitlement to subscribe for one New
Share for every three Existing Shares held on the Record Date (5.00pm
(NZDT), 20 February 2024) at the Issue Price. Eligible Shareholders
may take up some, or all, or none of their Rights.
If you do not take up all of your Rights, your shareholding percentage
in TruScreen will be diluted.
No Rights trading
The Rights will not be quoted on the NZX Main Board or the ASX,
and accordingly there will be no established market for Rights. If you
wish to sell your Rights privately to a buyer you identify, you should
contact the Registrar, Link Market Services (see Directory), to request
a Security Renunciation Form.
When to apply
Application (including postal applications) must be received by the
Closing Date (5:00pm (NZDT) on 13 March 2024, unless extended).

8
Key Terms of the Offer
How to apply
An application by an Eligible Shareholder must be made either:
• online at https://Truscreen.rightsoffer.co.nz. To complete an
online application, you will be required to enter your CSN/Holder
number; or
• by returning the Entitlement and Acceptance Form and following
the payment instructions on that form.
No UnderwritingThe Offer is not underwritten.
Dilution
Whilst an Eligible Shareholder is not obliged to participate in the
Offer, it is important to note that if an Eligible Shareholder chooses
not to participate in the Offer, then their shareholding will be diluted
down accordingly.
Important Dates
EventDate
Announcement of the Offer12 February 2024
Record Date5.00pm (NZDT) / 3.00pm (AEDT) on 20
February 2024
Opening Date for the Offer21 February 2024
Dispatch of Offer Documents and Entitlement and
Acceptance Forms
on or before 27 February 2024
Closing Date for the Offer5:00pm (NZDT) / 3.00pm (AEDT) on 13
March 2024
Shortfall Bookbuild opens14 March 2024
Shortfall Bookbuild closes5:00pm (NZDT) / 3.00pm (AEDT) on 15
March 2024
Allotment of New Shares, despatch of holder
statements and commencement of trading of New
Shares
20 March 2024
Payment of any refund from scaling of Offer and/or
Shortfall application
by 21 March 2024
The dates above are subject to change and are indicative only. TruScreen reserves the right to amend
this timetable (including by extending the Closing Date) subject to applicable laws and the Listing Rules.
TruScreen reserves the right to withdraw the Offer at any time at its absolute discretion.
8

9
Actions to be taken by
Eligible Shareholders
AVAILABLE ACTIONS
If you are an Eligible Shareholder,
accompanying this Offer Document is an
Entitlement and Acceptance Form showing
the number of Rights to subscribe for New
Shares that you are entitled to under the Offer.
You may take one or more of the following
actions:
• take up all or some of your Rights; or
• take up all of your Rights and apply for
additional New Shares under the Shortfall
Bookbuild (Shortfall Shares); or
• sell all or some of your Rights privately; or
• take up some of your Rights, and sell all or
some of the remaining balance privately; or
• do nothing with all of your Rights.
If you do nothing with your Rights before the
Closing Date, they will lapse and you will not be
able to subscribe for any New Shares under the
Offer.
The Offer is an offer to Eligible Shareholders only.
If you take up all of your Rights your percentage
shareholding in TruScreen will not reduce
(subject to TruScreen not issuing additional
New Shares in addition to those being offered
under this Offer), but if you do not take up all
your Rights, your percentage shareholding will
reduce following the completion of the Offer.
For example, if you hold 6,000 Shares on the
Record Date, you will have 2,000 Rights. If you
decide not to take up any of your Rights, and
all other shareholders do take up their Rights,
your percentage interest in TruScreen will be
diluted, however, you may receive some value
for your Rights under the Shortfall Bookbuild if
a Premium is payable.
TAKING UP YOUR ENTITLEMENT
Eligible Shareholders who wish to take up all or
some of their Rights should:
• complete their Entitlement and
Acceptance Form and deliver it to the
Share Registrar, along with payment of the
Issue Price in full by direct debit, by no later
than the Closing Date in accordance with
the instructions set out in the Entitlement
and Acceptance Form; or
• apply online in accordance with the
instructions for online applications on the
Entitlement and Acceptance Form.
There is no minimum number of New Shares
that you must subscribe for under the Offer.
Applicants will not be treated as having
offered to purchase a greater number of New
Shares than the number for which payment is
made.
APPLYING TO SUBSCRIBE FOR SHORTFALL
SHARES
Eligible Shareholders who wish to apply for
Shortfall Shares in excess of their Entitlement
may apply for an additional number of New
Shares through the Shortfall Bookbuild in
excess of the Rights they hold.
Eligible Shareholders may apply for Shortfall
Shares in the Shortfall Bookbuild through
the Acceptance Form or online application
process on the website for the offer https://
Truscreen.rightsoffer.co.nz, provided that the
Eligible Shareholder has taken up all of their
Rights in full, by applying for a dollar amount
of Shortfall Shares where provided on the
Application Form. If you do not accept your
Rights in full, your Application for any Shortfall
Shares will be disregarded.
The number of Shortfall Shares that you may
receive under the Shortfall Bookbuild will be
determined by TruScreen.
TruScreen may scale applications for Shortfall
Shares through the Shortfall Bookbuild,
including from Existing Shareholders, in such
manner as the directors of TruScreen consider
equitable and in the interests of TruScreen.
The directors’ decision on scaling will be final.

10
SELLING YOUR ENTITLEMENT
The Rights will not be quoted on the NZX Main
Board or the ASX, and accordingly there will
be no established market for Rights. If you
wish to sell your Rights privately to a buyer
you identify, you should contact Link Market
Services (see Directory) to request a Security
Renunciation Form.
Please note that if the buyer of your Rights
is an Ineligible Shareholder or a person that
would be an Ineligible Shareholder were they
a registered holder of Shares, that buyer will
not be able to take up the Rights they have
purchased.
Renunciations must be lodged with the Share
Registrar, Link Market Services Limited, not
later than the Closing Date (5.00pm (NZDT) on
13 March 2024). The Share Registrar’s details for
the return of your Entitlement and Acceptance
Form are set out in the Directory.
ACCEPTING SOME OF YOUR ENTITLEMENT
There is no minimum number of New Shares
that you must subscribe for under the Offer.
You may take up as many or as few of your
Rights as you wish. If you wish to take up some
of your Rights and sell the balance, you should:
• make arrangements privately to sell
the number of Rights you wish to sell
or, alternatively, wait for the Shortfall
Bookbuild under which you may receive
some value for the Rights you do not take
up if a Premium is payable; and
• indicate the number of New Shares
you wish to apply for in the Entitlement
and Acceptance Form and send your
completed Entitlement and Acceptance
Form to the Registrar, or submit your
Application online, together with payment
for the number of New Shares applied for.
If TruScreen receives, on or before the Closing
Date (5.00pm (NZDT) on 13 March 2024) both
an acceptance and a renunciation by an
Eligible Shareholder in respect of the same
Rights, effect will be given to the renunciation
in priority to the acceptance.
YOU MAY ELECT TO DO NOTHING
If you do nothing, your rights will lapse and
you will not be able to subscribe for any New
Shares. In this case, you may receive some
value for your Rights under the Shortfall
Bookbuild if a Premium is payable.
HOW TO APPLY FOR NEW SHARES
An application by an Eligible Shareholder must
be made either:
• online at https://truscreen.rightsoffer.
co.nz. To complete an online application,
you will be required to enter your CSN/
Holder number; or
• by returning the Entitlement and
Acceptance Form to the Registrar, and
following the payment instructions on that
form.
If you elect to subscribe for Shortfall Shares
through the Shortfall Bookbuild, you must
also make payment for both your Rights
entitlement, together with the dollar amount
that you wish to apply for under the Shortfall
Bookbuild.
In the event that all or part of your application
for New Shares in the Shortfall Bookbuild is not
successful, then TruScreen will refund any extra
application monies to you within five Business
Days of the Allotment Date.
By completing and returning an Entitlement
and Acceptance Form (or completing the
online application) and applying for New
Shares, you agree to accept the New Shares:
• subject to the terms set out in the
constitution of TruScreen; and
• on the terms set out in this Offer Document
and the Entitlement and Acceptance Form.
Your application is irrevocable and cannot be
withdrawn. TruScreen has the sole discretion
to accept or reject your application for New
Shares.
Actions to be taken by
Eligible Shareholders

11
PAYMENT
If you are an NZX Shareholder, you must:
• elect to apply using New Zealand dollars
at the NZ$ Offer Price; and
• pay for your New Shares by way of direct
debit.
If you are an ASX Shareholder, you must:
• elect to apply using Australian dollars at
the A$ price; and
• pay for your New Shares by way of BPAY
®
.
If you are a Custodian (or you hold your Shares
through a Custodian), please see paragraph
14.1 of Part 4: Terms of the Offer.
Cheques will not be accepted. Payment must
be made for both your Rights and the dollar
amount of additional New Shares that you are
applying for under the Shortfall (if any).
If any scaling is applied to the application for
Shortfall Shares under the Shortfall Bookbuild,
a refund of any extra application monies will
be processed within five Business Days of the
Allotment Date. Refunds will not be paid for
any difference arising solely due to rounding
or where the aggregate amount of the refund
payable to you is less than NZ$5.00.
More detail on payment options is included in
the Entitlement and Acceptance Form.
ENQUIRIES
If you have any queries about the number
of Rights shown on the Entitlement and
Acceptance Form which accompanies this
Offer Document, or how to complete the
Entitlement and Acceptance Form, please
contact the Share Registrar (refer to the
Directory for contact details).
Actions to be taken by
Eligible Shareholders

12
Overview of TruScreen
Group Limited
Overview
TruScreen Group Limited is listed on the NZX
Main Board. TruScreen is also listed on the ASX
as a Foreign Exempt Listing.
NATURE OF TRUSCREEN’S OPERATIONS AND
MAIN ACTIVITIES OF THE TRUSCREEN GROUP
Who is TruScreen
TruScreen Group Limited (NZX/ASX: TRU) is a
New Zealand-based medical device company
that has developed and commercialises an
AI-enabled device for detecting abnormalities
in the cervix in real-time via measurements
of the low level optical and electrical stimuli
responses.
TruScreen’s cervical cancer screening
technology enables cervical screening without
collecting tissue and processing of tissues
in laboratories, providing immediate result,
at the point of care. The technology avoids
patient’s discomfort, failed samples, missed
follow-up, and the need for costly, specialised
personnel and expensive laboratory
infrastructure. TruScreen’s works closely
with network of international distributors.
It enables TruScreen to hold intellectual
property in Australia and New Zealand while
maximising the commercial outreach globally.
The distributors hold the local knowledge
and manage the relationships with diverse
stakeholders. The key revenue stream comes
from the disposable consumable, Single
Use Sensor (SUS), used only once for each
examination with TruScreen
®
Ultra device.
The TruScreen device, TruScreen
®
Ultra, is
a class 2a medical device, registered as a
primary screening tool for cervical cancer .
The device is EU certified (CE Mark), ISO 13485
compliant and is registered for clinical use
with the TGA (Australia), MHRA (UK), NMPA
(China), SFDA (Saudi Arabia), Roszdravnadzor
(Russia), and COFEPRIS (Mexico). It has
Ministry of Health approval for use in Vietnam,
Zimbabwe, Israel, Ukraine, and the Philippines,
among others and has active distributors in 20
countries. It is also National Medical Products
Administration (NMPA) approved for sale in
China. It is also approved by COFEPRIS for
use in the public health sector of Mexico. In
2021, TruScreen established a manufacturing
facility in China for devices marketed and
sold in China as a domestic, Made In China
medical device. China remains the TruScreen’s
largest market, accounting for 65% of its sales
in FY2023, as well as the market with the
highest growth potential with up to 404m
women of addressable screening age. In
2023, the technology has been endorsed and
recognised in a China Blue Paper “Cervical
Cancer Three Stage Standardized Prevent
and Treatment” and was also included in the
CSCCP (Chinese Society of Colposcopy and
Cervical Pathology) China Cervical Cancer
Screening Management Guideline. These
important milestone national guidelines were
based on independently generated body of
evidence supporting TruScreen clinical use
world-wide and after extensive consultations
with healthcare practitioners and decision
makers.
In FY2023 alone, over 140,000 units of SUS
were sold world-wide. In the first 9 months
to 31 December 2023, the sales of SUS have
exceeded this. By the end of 2023 calendar
year, over 300 devices have been installed and
used in China, Vietnam, Mexico, Zimbabwe,
Russia, and Saudi Arabia.
TruScreen’s vision is ”A world without the cervical
cancer”. In 2019, World Health Organisation
(WHO) launched a strategy to eliminate
cervical cancer as the first ever cancer from
humanity by the end of this century. To date,
over 150 countries have committed to the WHO
targets. The WHO strategy comprises a target
for screening of eligible women, and TruScreen
provides a solution to many countries that are
struggling to reduce the mortality from one of
the biggest killer diseases of women world-
wide.
To learn more, please visit: www.truscreen.com

13
Overview of TruScreen
Group Limited
Our Strategy
TruScreen seeks to further develop and
expand its sales and distribution channels to
increase sales of its device and its consumable
SUS in its targeted and new markets. Several
initiatives to improve financial performance
are in place. TruScreen has the following short-
term strategy:
• Rapidly expand sales in China, leveraging
off the China manufacture facility which
allows TruScreen to access the China
market with its domestic “Made In China”
product.
• Support and develop other key Low- and
Middle-Income Country (LMICs) markets of
Vietnam, Zimbabwe (as base to expand
in Africa), Mexico (as base to expand to
Central and South America), Poland (as
base to expand in Central and Eastern
Europe), Saudi Arabia (as base to expand
in Middle Easter and Gulf States) and
Central Asia using the existing distributor
in Russia/Kazakhstan.
• Working closely with its exclusive SUS
manufacturer to reduce SUS and logistic
costs for margin improvements; and
• Gaining market access through Health
Technology Economic Assessments to
assist regulators and healthcare decision
makers to adopt TruScreen as a preferred
cervical screening method.
Recent Milestones
In CY2023, TruScreen has grown its presence
in China and capitalising on advancing into
3 focus markets: Zimbabwe, Middle East and
Vietnam.
A major milestone was the recent recognition
and endorsement of the technology in a
China Blue Paper “Cervical Cancer Three
Stage Standardized Prevent and Treatment”
published on 28 April 2023. In China, Blue
Papers are promulgated as the definitive
position on leading edge developments in all
industries and are recognised as an endorsed
guidelines by the leaders in the relevant field.
The July 2023 edition of the CSCCP (Chinese
Society of Colposcopy and Cervical
Pathology) China Cervical Cancer Screening
Management Guideline also recognised
TruScreen as a new method for cervical
cancer screening. The decision was based on
the body of evidence supporting TruScreen
clinical use world-wide and after extensive
consultations with healthcare practitioners
and decision makers. These are the first
national medical guidelines in the world to
recommend TruScreen.
China’s operation, through its distributor
SWXT, is growing rapidly on the recent
recognitions outlined above. To date, more
than 100 devices are installed in hospitals and
clinics in 22 provinces. In addition, the sales
pipeline includes: 14 Hospital tenders won
and awaiting installation, 26 hospitals which
have approved TruScreen and are awaiting
tender and 74 Hospitals where TruScreen has
obtained OBGYN department acceptance,
awaiting hospital approval.
TruScreen sales grew by 40% YOY in the nine
months to 31 December 2023, from the positive
impact of the guidelines and post-Covid-19
market recovery.
Positive traction after significant efforts over
past years saw TruScreen’s development in
other markets is now happening. TruScreen has
recently commenced commercial operations
in the largest private hospital network in Saudi
Arabia when distributor BettaLife won a tender
at the Dr Sulaiman Al-Habib Medical Group.
Private health services provider Dr. Sulaiman
Al-Habib Medical Group (DSAMG) completed
its first clinical evaluation in the Middle East,
of 507 women. TruScreen’s results showed that
sensitivity was 83.3% and specificity was 95%,
compared to 83.3% and 98% for the placebo
Liquid Based Cytology (LBC). This confirmed
TruScreen’s efficacy while providing real time
results and resolving many of the issues faced
with patient follow-up when using LBC. The
clinical evaluation manuscript of the study is
in submission for publication in the European
Journal of Gynaecology.

14
Overview of TruScreen
Group Limited
In Zimbabwe, the Ministry of Health’s
collaboration with the National Aids Council
screening program in Masvingo Province is
continuing with 14,000 women screened to
date.
In Poland, TruScreen was listed on the
Innovation Register by the Polish Ministry
of Health increasing awareness among
specialists and clinicians. This country has an
‘at risk’ population of 17.1m and high cervical
cancer rates (3,515 cases and 1,858 deaths in
2022) due to the lack of a national screening
program. TruScreen was recently awarded the
Polish Mother and Child Institute (MCI) Start
Up Challenge as one of top 2 winners among
51 international submissions of advanced,
innovative technologies, focused on artificial
intelligence and data acquisition in healthcare.
TruScreen’s distributor in Mexico, Sunbird
Medical has recently successfully gain
approval to access to the public health sector
from COLEPRISs, the national regulator. This
positive approval will see TruScreen being
available to both the private and public
health sectors’ hospitals and clinics. A major
milestone.
What’s Next for TruScreen
Longer term, TruScreen will:
• Expand its existing market presence to
new, large population markets in Africa,
Gulf States, and others;
• Add new healthcare products and services
to its portfolio; and
• Expand application for the technology in
screening for diverse range of cancers.
People
The TruScreen team have a wealth of
experience in medical devices and market
experience. For further details see http://
nzx-prod-s7fsd7f98s.s3-website-ap-
southeast-2.amazonaws.com/attachments/
TRU/414041/397705.pdf
Regulatory
Truscreen has incurred significant cost of
~$400,000 over the past 2 years in complying
with the new global medical device
regulations – MDR effective 2025 and NMPA
(China) recently completed.
Further Resources
Scientific publications 2020-2022:
• Fei Chen et al., COGA
Presentation#001051: Evaluation of an
AI Powered Optoelectronic Technology
in Cervical Cancer Screening, American
Society of Colposcopy ad Cervical
Pathology Annual Congress in San Diego,
California, 2022
• Jessica N Vet et al., A Performance
Evaluation of an Optoelectronic Cervical
Screening Device in Comparison to
Cytology and HPV DNA Testing, Eur. J.
Gynaecol. Oncol. 2022; 43(2): 213–218
http://doi.org/10.31083/j.ejgo4302027
• Y. Wei, W. Wang, M. Cheng et al., Clinical
evaluation of a real-time optoelectronic
device in cervical cancer screening,
European Journal of Obstetrics
& Gynecology and Reproductive
Biology, https://doi.org/10.1016/j.
ejogrb.2021.09.027
• Comparison of the detection rate of
cervical lesion with TruScreen, LBC test
and HPV test: A Real-world study based
on population screening of cervical
cancer in rural areas of China, Yu Ma,
Jiangli Di , Hui Bi, et al., https://doi.
org/10.1371/journal.pone.0233986

15
Terms of the Offer
THE OFFER
The Offer is an offer of New Shares in TruScreen
to Eligible Shareholders under a pro-rata
renounceable rights issue, followed by a
Shortfall Bookbuild. Under the Offer, Eligible
Shareholders are entitled to subscribe for
one (1) New Share for every three (3) Existing
Shares held on the Record Date. Any fractional
Entitlements will be rounded down to the
nearest whole number.
The New Shares will be of the same class as,
and rank equally with, the Existing Shares
which are quoted on the NZX Main Board and
the ASX. It is a term of the Offer that TruScreen
will take any necessary steps to ensure that
the New Shares are quoted immediately after
the issue.
Eligible Shareholders who take up their Rights
in full may also apply for additional Shortfall
Shares under the Shortfall Bookbuild.
The maximum number of New Shares being
offered under the Offer is 140,008,446 New
Shares.
ISSUE PRICE AND APPLICATION MONIES
The Issue Price under the Offer is NZ$0.02
(A$0.0187) per New Share. The A$ price has
been set by TruScreen taking into account
the A$:NZ$ exchange rate published by the
Reserve Bank of New Zealand on its website at
5pm on 5 February 2024.
Payment for the New Shares (together with any
additional Shortfall Shares applied for) must be
made in full on application with a completed
Entitlement and Acceptance Form delivered to
the Share Registrar, or by completing an online
application at https://Truscreen.rightsoffer.
co.nz, in accordance with the instructions set
out in the Entitlement and Acceptance Form.
If you are an NZX Shareholder, you must elect
to apply using New Zealand dollars at the NZ$
price. If you are an ASX Shareholder, you must
elect to apply using Australian dollars at the
A$ price.
TruScreen may (at its discretion) accept late
applications and Application Monies, but has
no obligation to do so. TruScreen may accept
or reject (at its discretion) any Entitlement and
Acceptance Form which it considers is not
completed correctly, and may correct any
errors or omissions on any Entitlement and
Acceptance Form.
If an Eligible Shareholder does not renounce
their Rights and does not apply for any New
Shares and pay the associated Application
Monies by the Closing Date (5.00pm (NZDT) on
13 March 2024), their Rights will lapse.
Application Monies received will be held in a
trust account with the Share Registrar until
the corresponding New Shares are allotted or
the Application Monies are refunded. Interest
earned on the Application Monies will be
for the benefit, and remain the property, of
TruScreen and will be retained by TruScreen
whether or not the issue and allotment of New
Shares takes place.
Any refunds of Application Monies will be
made within five Business Days of allotment,
or, if a decision is made not to proceed with
the Offer, within five Business Days of the date
of that decision.
Once submitted, and subject to all applicable
law, an Application is irrevocable and cannot
be withdrawn.

16
Terms of the Offer
ELIGIBILITY
The Offer is only open to Eligible Shareholders
or persons that TruScreen is satisfied can
otherwise participate in the Offer in compliance
with all applicable laws.
TruScreen considers that the legal
requirements of jurisdictions other than New
Zealand and Australia are such that it would
be unduly onerous for TruScreen to make the
Offer in those jurisdictions. This decision was
made having regard to the small number of
Shareholders in such overseas jurisdictions, the
financial resources of TruScreen and the costs
of complying with overseas legal requirements.
This Offer Document is intended for use only
in connection with the Offer to any person
recorded in TruScreen’s share register as a
Shareholder on the Record Date (5.00pm
(NZDT) 20 February 2024):
• whose address is shown in TruScreen’s
share register as being in New Zealand; or
• whose address is shown in TruScreen’s
share register as being in Australia.
This Offer Document is not to be sent or
given to any person outside New Zealand or
Australia in circumstances in which the Offer or
distribution of this Offer Document would be
unlawful.
OPENING AND CLOSING DATES
The Offer will open for receipt of acceptances
from 21 February 2024 (Opening Date). The last
day for receipt of the completed Acceptance
and Entitlement Form with payment is 5.00pm
(NZDT) on 13 March 2024 (Closing Date),
subject to TruScreen varying those dates in
accordance with the Listing Rules.
NO RIGHTS TRADING
The Rights will not be quoted on the NZX Main
Board or the ASX, and accordingly there will
be no established market for Rights. If you
wish to sell your Rights privately to a buyer you
identify, you should contact the Registrar, Link
Market Services (see Directory), to request a
Security Renunciation Form.
Please note that if the buyer of your Rights
is an Ineligible Shareholder or a person that
would be an Ineligible Shareholder were they
a registered holder of Shares, that buyer will
not be able to take up the Rights they have
purchased.
APPLING FOR SHORTFALL SHARES
Eligible Shareholders who take up all of their
Rights are entitled to apply for Shortfall Shares
under the Shortfall Bookbuild.
Any New Shares in respect of which Rights are
not taken up will form the Shortfall and will
be available to Applicants who subscribe for
New Shares in addition to their entitlement, as
well as other investors. Accordingly, Applicants
may apply for additional New Shares in excess
of the Rights they hold, subject to the resulting
availability.
TruScreen reserves the right to determine
who, other than Eligible Shareholders, may
participate in the Shortfall Bookbuild and may
decline or scale applications for New Shares
by any Eligible Shareholder.
Eligible Shareholders who wish to participate
in the Shortfall Bookbuild may do so, provided
they have fully taken up all of their Rights by:
• in the case of NZX Shareholders, specifying
the NZ$ amount of New Shares they
wish to apply for on the Entitlement and
Acceptance Form where provided; or
• in the case of ASX Shareholders, specifying
the A$ amount of New Shares they wish
to apply for on the Entitlement and
Acceptance Form where provided,
and must pay that NZ$ or A$ amount of
additional New Shares being applied for under
the Shortfall in addition to their Application
Monies for their Rights.

17
Terms of the Offer
SHORTFALL BOOKBUILD
New Shares attributable to the Shortfall will
be offered to Eligible Shareholders who take
up their Rights in full, and other investors,
under the Shortfall Bookbuild. If you do not
take up your Rights under the Rights Offer or
are an Ineligible Shareholder, the New Shares
attributable to your Shortfall will be offered for
sale in the Shortfall Bookbuild.
Shortfall Bookbuild process
Eligible Shareholders that take up their Rights
in full can apply for New Shares by specifying
the dollar value of New Shares for which you
wish to apply at the time you complete and
return the Entitlement and Acceptance Form
to exercise your Rights. The price at which
the New Shares will be issued to Eligible
Shareholders is the Bookbuild Price to be set
as described below.
Other investors participating in the Shortfall
Bookbuild may bid for New Shares equal in
number to the Shortfall. The minimum bid that
may be submitted for a New Share under the
Shortfall Bookbuild is the Issue Price of NZ$0.02
per New Share and this amount is payable to
Truscreen.
The Bookbuild Price will be determined by
Truscreen and will be:
• no less than the Issue Price; and
• no more than the closing price on the
NZX Main Board for an Existing Share as
at the close of trading on the day prior to
the Shortfall Bookbuild (unless the closing
price is less than the Issue Price, in which
case the Bookbuild Price will be equal to
the Issue Price).
The Bookbuild Price will be set in NZ$ and then
converted to A$ at the prevailing exchange
rate available to Truscreen at the time the
price is set. The proceeds from each New Share
issued under the Shortfall Bookbuild (if any) will
be paid by the Share Registrar as follows:
• the Issue Price of NZ$0.02 to Truscreen; and
• any Premium achieved to the holders of
unexercised Rights (including Ineligible
Shareholders) in proportion to their
holdings of unexercised Rights. Ineligible
Shareholders will be deemed to hold the
number of Rights they would have received
if they were Eligible Shareholders for the
purpose of calculating the amount of any
Premium payable to them.
Example
This example assumes that there is demand
for all of the New Shares available under the
Shortfall Bookbuild and that the Bookbuild
Price exceeds the Issue Price.
Issue Price per New Share: $0.02
Bookbuild Price per New Share: $0.025
Premium: $0.005
In this example, a Shareholder who holds
12,000 Existing Shares at 5.00pm on the Record
Date who is either an Ineligible Shareholder
or is an Eligible Shareholder who chooses not
to take up any of his or her Rights will have
4,000 unexercised Rights. That Shareholder
will receive $20 in aggregate for his or her
unexercised Rights in the Shortfall Bookbuild,
being the Premium of $0.005 multiplied by the
number of unexercised Rights held by him or her.
The above is an example only. There is no
guarantee that the Bookbuild Price will exceed
the Issue Price.
If the Bookbuild Price is equal to the Issue
Price, there will be no Premium payable to the
holders of unexercised Rights.
Application to participate in Shortfall
Bookbuild
If you are an Eligible Shareholder and you have
taken up all of your Rights, you may participate
in the Shortfall Bookbuild by applying online, or
completing the Entitlement and Acceptance
Form, and applying for a dollar amount of New
Shares at the Bookbuild Price.

18
Terms of the Offer
If you are an investor who is not an Eligible
Shareholder, you may participate in the
Shortfall Bookbuild by contacting Truscreen at
info@truscreen.com who will provide details as
to the process to be undertaken in relation to
the Shortfall Bookbuild. Participation in the
Shortfall Bookbuild will be limited to Eligible
Shareholders and such other investors in New
Zealand and other jurisdictions who Truscreen
is satisfied may participate in the Shortfall
Bookuild under all applicable laws without the
need for any registration, lodgement or other
formality (other than a formality with which
Truscreen is willing to comply)
Shortfall Bookbuild allocation policy
Allocations and any necessary scaling of
applications for New Shares under the Shortfall
Bookbuild will be determined by Truscreen
in its discretion. The allocation policy will be
influenced by, but not constrained by factors
such as:
• the number of New Shares bid for by
particular bidders;
• the timeliness of the bid by particular
bidders with a likely preference for early
bids;
• the price at which the bid is made, with
a preference for bids in excess of the
Issue Price and demonstration of price
leadership;
• the prospects of success of the Offer; and
• any other factors that Truscreen consider
appropriate.
Once the Bookbuild Price has been
determined, the application monies in respect
of any applications for New Shares through the
Shortfall Bookbuild by Eligible Shareholders will
be divided by the Bookbuild Price to calculate
the number of New Shares that those Eligible
Shareholders have applied for, rounded
down to the nearest whole New Share. Any
refunds of application monies due to scaling
of applications or applications not being
accepted under the Shortfall Bookbuild will be
made within five business days (as defined in
the Listing Rules) of allotment (without interest).
Payment of Premium
The Premium, if any, will be paid by the
Share Registrar in New Zealand or Australian
dollars in accordance with the direct credit
payment instructions provided by the relevant
Shareholder to Truscreen (if any). No interest
will be paid in respect of any Premium payable.
Payment (if any) is expected to be made by 18
March 2024.
ALLOTMENT OF NEW SHARES
New Shares issued pursuant to the exercise
of Entitlements or under the Shortfall are
expected to be allotted and issued by 20
March 2024 (Allotment Date). Transaction
statements confirming the allotment of your
New Shares will be issued and mailed in
accordance with the Listing Rules.
QUOTATION OF NEW SHARES
The New Shares have been accepted for
quotation by NZX and will be quoted upon
completion of allotment procedures. The NZX
Main Board is a licensed market operated
by NZX, which is a licensed market operator
regulated under the FMCA. An application will
also be made by TruScreen for the New Shares
to be issued under the Offer to be quoted on
ASX.
However, neither NZX nor ASX accepts
responsibility for any statement in this Offer
Document. The fact that ASX may approve
the New Shares for quotation is not to be
taken in any way as an indication of the merits
of TruScreen.
CUSTODIANS
Under the Offer, a custodian (Custodian) is
any Eligible Shareholder having a registered
address in New Zealand or Australia, that:
a. is a trustee corporation or a nominee
company and holds Shares in TruScreen
by reason only of acting for another person
in the ordinary course of business of that
trustee corporation or nominee company;
or
b. holds Shares in TruScreen by reason only of
being a bare trustee of a trust to which the
Shares are subject.

19
Terms of the Offer
Custodians must confirm to TruScreen that they
are holding Existing Shares as a Custodian for
one or more beneficial owners (Participating
Beneficiary) and certify the matters described
below by email, together with the Custodian’s
Application Form.
a. the number of Participating Beneficiaries
and their names and addresses;
b. in respect of each of the Participating
Beneficiaries;
(i) the number of Existing Shares that the
Custodian holds on behalf of each
Participating Beneficiary and the
number and dollar amount of Rights;
and
(ii) the dollar amount of any additional
New Shares in the Shortfall (if eligible),
that each Participating Beneficiary has
instructed the Custodian, either directly
or indirectly through a Downstream
Custodian, to apply for on their behalf;
c. that a copy of this document was given to
each Participating Beneficiary; and
d. where the Custodian holds Shares on
behalf of a Participating Beneficiary
indirectly, through one or more Downstream
Custodians, the name and address of each
Downstream Custodian.
Custodians may not distribute this Offer
Document to any person in any country
outside New Zealand and Australia.
TERMS AND RANKING OF NEW SHARES
New Shares allotted and issued will be fully
paid and will be the same class as, and rank
equally in all respects with, Existing Shares on
issue that are quoted on the Main Board on the
Allotment Date. They will give the holder the
right to one vote on a resolution at a meeting
of Shareholders (subject to any restrictions in
TruScreen’s constitution or the Listing Rules),
the right to dividends authorised by the Board
and the right to a proportionate share in any
distribution of surplus assets of TruScreen on
any liquidation. Applicants for New Shares
will be bound by TruScreen’s constitution and
the terms of the Offer set out in this Offer
Document.
NO MINIMUM AMOUNT TO BE RAISED
There is no minimum amount that must be
raised for the Offer to proceed.
AMENDMENTS TO THE OFFER AND WAIVER OF
COMPLIANCE
Notwithstanding any other term or condition
of the Offer, TruScreen may at its discretion:
• make non-material modifications to the
Offer on such terms and conditions as it
sees fit (in which event applications for
Shares under the Offer will remain binding
on the Applicant notwithstanding such
modification and irrespective of whether
an application was received by the
Registrar before or after such modification
is made); and/or
• suspend or terminate the Offer at any
time prior to the issue of the New Shares
under the Offer (including by reviewing
the timetable for the Offer). If the Offer is
terminated, application monies will be
refunded to Applicants without interest
within 5 Business Days of termination.
TruScreen reserves the right to waive
compliance with any provision of these terms
and conditions.
TruScreen will notify NZX and ASX of any
waiver, amendment, variation, suspension,
withdrawal or termination of the Offer.
BROKERAGE
No brokerage is payable by Eligible
Shareholders who accept their Entitlement.
GOVERNING LAW
This Offer Document, the Offer and any
contract resulting from it are governed by the
laws of New Zealand, and each Applicant
submits to the exclusive jurisdiction of the
courts of New Zealand.

20
Glossary
Allotment Date
means the date for allotment of New Shares under the Offer,
expected to be on or about 20 March 2024.
Applicant
means an investor whose application for New Shares has been
received by the Registrar.
Application
means an application to subscribe for New Shares under this Offer
Document.
Application Monies
means monies received from Applicants in respect of their
Applications.
ASICmeans the Australian Securities and Investments Commission.
ASX
means ASX Limited or the Australian Securities Exchange operated
by ASX Limited, as the context may require.
ASX Shareholder
means an Eligible Shareholder whose Existing Shares are held on
TruScreen’s ASX branch register on the Record Date.
Boardmeans the board of directors of TruScreen.
Bookbuild Price
The price per New Share determined by Truscreen through the
Shortfall Bookbuild process based on the bids received.
Business Dayhas the meaning given to that term in the Listing Rules.
Closing Datemeans 5:00pm (NZDT) on 13 March 2024.
Eligible Shareholder
means a Shareholder who as at the Record Date is registered as
a Shareholder, and has a registered address in New Zealand or
Australia.
Entitlement
means the number of Rights to which Eligible Shareholders are
entitled.
Entitlement and Acceptance
Form
means the personalised entitlement and acceptance form
accompanying this Offer Document for Eligible Shareholders.
Existing Sharemeans a Share on issue on the Record Date.
Ineligible Shareholdersmeans Shareholders other than Eligible Shareholders.
Issue Pricemeans NZ$0.02 (A$0.0187) per New Share.
Listing Rulesmeans the NZX Listing Rules.
Main Boardmeans the NZX Main Board.
New Share
means an ordinary share in TruScreen offered under the Offer of
the same class as (and ranking equally in all respects with) Existing
Shares at the time of allotment of the New Shares.

21
Glossary
NZXmeans NZX Limited.
NZX Firm
means an entity designated as an NZX Firm under the Participant
Rules of NZX.
NZX Shareholder
means an Eligible Shareholder whose Existing Shares are held on
TruScreen’s NZX branch register on the Record Date.
Offer
means the offer of New Shares to Eligible Shareholders as at the
Record Date, under the renounceable rights offer set out in this Offer
Document, together with the Shortfall Bookbuild.
Offer Documentmeans this document.
Opening Datemeans 21 February 2024.
Premium
The amount per New Share, if any, by which the Bookbuild Price
exceeds the Issue Price.
Record Datemeans 5:00pm (NZDT) on 20 February 2024.
Registrar or Share Registrarmeans Link Market Services Limited, Auckland.
Right
means the renounceable right to subscribe for 1 New Share for every
3 Existing Shares held on the Record Date at the Issue Price, issued
pursuant to the Offer.
Sharemeans one fully paid ordinary share in TruScreen.
Shareholdermeans a registered holder of Shares on issue.
Shortfall means the number of Rights not exercised by Shareholders.
Shortfall Sharesmeans New Shares available under the Shortfall Bookbuild
Shortfall BookbuildThe bookbuild process a number of New Shares equal to the Shortfall.
TruScreenmeans TruScreen Group Limited.

22
ISSUER
TruScreen Group Limited
c/- HLB Mann Judd Limited
Level 6, Equitable House
57 Symonds Street, Grafton
Auckland, 1010
New Zealand
T: +64 9 303 2243
E: hlb@hlb.co.nz
DIRECTORS OF TRUSCREEN GROUP LIMITED
Anthony Ho (Chairman)
Dexter Cheung
Christopher Horn
Juliet Hull
EXECUTIVE MANAGEMENT
Dr. Beata Edling (CEO)
Guy Robertson (CFO)
Directory
REGISTRAR
Link Market Services Limited
PwC Tower
Level 30/15 Customs Street West
Auckland CBD, 1010
PO Box 91976
Victoria Street West
Auckland 1142
Toll free: 0800 990 057
T: 64 9 375 5998
W: linkmarketservices.co.nz
E: enquiries@linkmarketservices.co.nz
LEGAL ADVISORS
NZ legal advisor:
Sean Joyce – Corporate Counsel
PO Box 42 258, Orakei
Auckland 1745
Australian legal advisor:
Addisons
Level 12, 60 Carrington Street
Sydney NSW 2000
www.addisons.com